NCT05116462View on ClinicalTrials.gov

Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

506

Participants

Timeline

Start Date

March 15, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

October 14, 2028

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Pemetrexed

500 mg/m2 D1 IV Q3W

DRUG

Carboplatin

AUC 5 or 6 mg/ml/min D1 IV Q3W

DRUG

Paclitaxel

175 or 200 mg/m2 D1 IV Q3W

DRUG

Sintilimab

200 mg D1 IV Q3W

DRUG

Cisplatin

75 mg/m2 D1 IV Q3W

DRUG

Nab paclitaxel

100 mg/m2 D1, 8, 15 IV Q3W

DRUG

Placebo

20 ml D1 IV Q3W

Trial Locations (1)

200433

Shanghai Pulmonary Hospital, Shanghai

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT05116462 - Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer | Biotech Hunter | Biotech Hunter